1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
AVAX Technologies, Inc.

AVAX Technologies, Inc.

AVXT
AVAX Technologies, Inc.US flagOther OTC
0.00
USD
- -
- -
6,894.00Market Cap
1996 Y
1997 Y
1998 Y
1999 Y
2000 Y
2001 Y
2002 Y
2003 Y
2004 Y
2005 Y
2006 Y
2007 Y
TTM
Revenue per Share
0.03
0.03
- -
- -
0.01
0.03
0.05
0.05
0.06
0.03
0.01
0.01
0.01
Basic EPS, GAAP
-0.48
-1.15
-1.01
-0.74
-1.06
-0.91
-0.57
-0.19
-0.12
-0.07
-0.09
-0.05
-0.05
Free Cash Flow per Basic Share
-0.42
-1.07
-1.08
-0.88
-0.69
-0.66
-0.56
-0.21
-0.1
-0.07
-0.07
-0.04
-0.05
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-1.06
-2
-2.34
-2
-2.44
-3.18
-3.75
-3.73
-2.33
-1.32
-1.26
-0.7
-0.63
Tangible Book Value per Share
6.36
4.21
1.8
1.38
1.83
0.78
0.22
0.03
0.03
0.1
- -
0.03
-0.02
Basic Weighted Avg Shares
3
4
6
11
15
17
17
18
29
55
61
119
142
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
1
1
1
2
2
1
1
1
Operating Margin (%)
-1,900
-5,000
-649,999,900
-855,197,200
-11,017.96
-2,910.27
-1,218.81
-350.73
-197.53
-236.81
-748.35
-1,084.07
-1,023.22
Depreciation Expense
- -
- -
- -
- -
- -
- -
1
- -
1
- -
- -
- -
- -
Net Income, GAAP
-2
-4
-6
-8
-16
-15
-9
-3
-3
-4
-5
-6
-7
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-1,500
-4,300
-580,000,000
-786,756,300
-14,473.5
-2,791.1
-1,222.92
-353.07
-204.48
-228.11
-728.86
-1,038.84
-1,004.42
Working Capital
20
16
9
12
22
11
2
-1
- -
4
-1
2
-3
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
20
16
10
15
28
13
4
1
1
6
- -
3
-2
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Mar'08
Jun'08
Sep'08
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
142
142
142
Market Capitalization
12
13
6

Working Capital

FRC

•

in mil. unless spec.
Mar'08
Jun'08
Sep'08
Total Current Assets
4
2
1
Cash, Cash Equivalents & STI
3
1
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
3
3
3
Payables & Accruals
3
2
3
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
110.42%
225.77%
884.13%
Free Cash Flow
8.59%
-4.05%
17.54%
Net Income, GAAP
14.42%
2.31%
19.76%
Sales/Revenue/Turnover
- -
5.55%
-15.98%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2006
- -
- -
- -
- -
1
2007
- -
- -
- -
- -
1
2008
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2006
-0.02
-0.02
-0.02
- -
-0.09
2007
-0.02
-0.01
-0.01
- -
-0.05
2008
-0.01
-0.01
-0.01
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2006
- -
- -
- -
- -
- -
2007
- -
- -
- -
- -
- -
2008
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Adele Sommerfeld
Full Time Employees
9
Sector
Healthcare
Industry
Biotechnology
Address
2000 Hamilton Street Philadelphia PA United States of America 19130
IPO Date
May 15, 1997
Website
avax-tech.com
Similar Companies
Bionomics Limited (BNOEF)
Evgen Pharma plc (EVG.L)
Precision BioSciences, Inc. (DTIL)
Imago BioSciences, Inc. (IMGO)
Biotest AG (BIO.DE)
Incyte Corporation (0J9P.L)
Business
AVAX Technologies, Inc. AVAX Technologies, Inc. (AVXT) is a development-stage biotechnology company focused on the development and commercialization of autologous cell (AC) vaccine technologies for cancer immunotherapy. The company offers core product candidates including MVax, an immunotherapy vaccine for post-surgical treatment of stage III/IV melanoma that has completed phase III clinical trials and demonstrated a 44% five-year overall survival rate in prior studies; OVax, a phase I/II vaccine for relapsed stage III/IV ovarian cancer with median survival of 22.7 months reported in 2016; and LungVax for non-small cell lung cancer, alongside contract biological manufacturing services for other biopharmaceutical firms. Founded in 1990 and headquartered in Philadelphia, Pennsylvania, with historical operations in Kansas and France, AVAX Technologies targets oncology markets primarily in the United States and serves patients with life-threatening cancers through individualized therapies. Recent developments include maintenance of its phase III MVax trial status under FDA Special Protocol Assessment, ongoing listings on OTC markets as of 2025, and no major acquisitions, partnerships, or funding rounds announced in the past 1-2 years, reflecting its continued emphasis on immuno-oncology pipeline advancement amid a dormant commercial stage.

Company News

APIChat

  • defenseworld.net

    Reviewing AVAX Technologies (OTCMKTS:AVXT) & Anixa Biosciences (NASDAQ:ANIX)